Zurcher Kantonalbank Zurich Cantonalbank Buys 6,797 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kura Oncology, Inc. (NASDAQ:KURA) by 70.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 16,393 shares of the company’s stock after purchasing an additional 6,797 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Kura Oncology were worth $236,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale raised its position in Kura Oncology by 216.7% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 95,000 shares of the company’s stock valued at $1,343,000 after purchasing an additional 65,000 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Kura Oncology by 18.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 563,421 shares of the company’s stock valued at $5,138,000 after purchasing an additional 86,141 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Kura Oncology by 10.9% in the third quarter. Bank of New York Mellon Corp now owns 261,744 shares of the company’s stock valued at $2,387,000 after purchasing an additional 25,677 shares during the last quarter. Jupiter Asset Management Ltd. raised its holdings in Kura Oncology by 234.2% in the third quarter. Jupiter Asset Management Ltd. now owns 57,877 shares of the company’s stock worth $528,000 after purchasing an additional 40,560 shares in the last quarter. Finally, Walleye Capital LLC grew its stake in Kura Oncology by 220.4% during the 3rd quarter. Walleye Capital LLC now owns 264,893 shares of the company’s stock worth $2,416,000 after buying an additional 182,221 shares during the last quarter.

Kura Oncology Stock Up 1.8 %

Shares of KURA opened at $21.01 on Tuesday. Kura Oncology, Inc. has a one year low of $7.41 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67. The stock has a 50 day moving average price of $20.66 and a 200 day moving average price of $16.13. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -9.68 and a beta of 0.89.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.50) EPS. Equities research analysts forecast that Kura Oncology, Inc. will post -2.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KURA. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Friday. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Friday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $28.28.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.